Literature DB >> 34127507

CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer?

Alexandra M Miggelbrink1,2, Joshua D Jackson3, Selena J Lorrey1,4, Ethan S Srinivasan1,5, Jessica Waibl-Polania1,2, Daniel S Wilkinson1, Peter E Fecci6,2,3,4.   

Abstract

In chronic infections and in cancer, persistent antigen stimulation under suboptimal conditions can lead to the induction of T-cell exhaustion. Exhausted T cells are characterized by an increased expression of inhibitory markers and a progressive and hierarchical loss of function. Although cancer-induced exhaustion in CD8 T cells has been well-characterized and identified as a therapeutic target (i.e., via checkpoint inhibition), in-depth analyses of exhaustion in other immune cell types, including CD4 T cells, is wanting. While perhaps attributable to the contextual discovery of exhaustion amidst chronic viral infection, the lack of thorough inquiry into CD4 T-cell exhaustion is particularly surprising given their important role in orchestrating immune responses through T-helper and direct cytotoxic functions. Current work suggests that CD4 T-cell exhaustion may indeed be prevalent, and as CD4 T cells have been implicated in various disease pathologies, such exhaustion is likely to be clinically relevant. Defining phenotypic exhaustion in the various CD4 T-cell subsets and how it influences immune responses and disease severity will be crucial to understanding collective immune dysfunction in a variety of pathologies. In this review, we will discuss mechanistic and clinical evidence for CD4 T-cell exhaustion in cancer. Further insight into the derivation and manifestation of exhaustive processes in CD4 T cells could reveal novel therapeutic targets to abrogate CD4 T-cell exhaustion in cancer and induce a robust antitumor immune response. ©2021 The Authors; Published by the American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 34127507      PMCID: PMC8563372          DOI: 10.1158/1078-0432.CCR-21-0206

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  147 in total

1.  PD-1/PD-L1 signal pathway participates in HCV F protein-induced T cell dysfunction in chronic HCV infection.

Authors:  Wen Xiao; Long Feng Jiang; Xiao Zhao Deng; Dan Yan Zhu; Jia Ping Pei; Mao Lei Xu; Bing Jun Li; Chang Jun Wang; Jing Hai Zhang; Qi Zhang; Zhen Xian Zhou; Wei Liang Ding; Xiao Dong Xu; Ming Yue
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

2.  Increased exhausted CD8+ T cells with programmed death-1, T-cell immunoglobulin and mucin-domain-containing-3 phenotype in patients with multiple myeloma.

Authors:  Jiaxiong Tan; Shaohua Chen; Jingying Huang; Youchun Chen; Lijian Yang; Chunli Wang; Jun Zhong; Yuhong Lu; Liang Wang; Kanger Zhu; Yangqiu Li
Journal:  Asia Pac J Clin Oncol       Date:  2018-06-25       Impact factor: 2.601

3.  CD4+ T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness.

Authors:  Tomasz Ahrends; Aldo Spanjaard; Bas Pilzecker; Nikolina Bąbała; Astrid Bovens; Yanling Xiao; Heinz Jacobs; Jannie Borst
Journal:  Immunity       Date:  2017-11-07       Impact factor: 31.745

4.  The Emergence and Functional Fitness of Memory CD4+ T Cells Require the Transcription Factor Thpok.

Authors:  Thomas Ciucci; Melanie S Vacchio; Yayi Gao; Francesco Tomassoni Ardori; Julian Candia; Monika Mehta; Yongmei Zhao; Bao Tran; Marion Pepper; Lino Tessarollo; Dorian B McGavern; Rémy Bosselut
Journal:  Immunity       Date:  2019-01-09       Impact factor: 31.745

5.  Intrinsic functional dysregulation of CD4 T cells occurs rapidly following persistent viral infection.

Authors:  David G Brooks; Luc Teyton; Michael B A Oldstone; Dorian B McGavern
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

6.  Restoring function in exhausted CD8 T cells during chronic viral infection.

Authors:  Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Nature       Date:  2005-12-28       Impact factor: 49.962

7.  An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction.

Authors:  Chen Zhu; Kaori Sakuishi; Sheng Xiao; Zhiyi Sun; Sarah Zaghouani; Guangxiang Gu; Chao Wang; Dewar J Tan; Chuan Wu; Manu Rangachari; Thomas Pertel; Hyun-Tak Jin; Rafi Ahmed; Ana C Anderson; Vijay K Kuchroo
Journal:  Nat Commun       Date:  2015-01-23       Impact factor: 14.919

8.  Human Immunodeficiency Virus Type-1 Elite Controllers Maintain Low Co-Expression of Inhibitory Receptors on CD4+ T Cells.

Authors:  Kajsa Noyan; Son Nguyen; Michael R Betts; Anders Sönnerborg; Marcus Buggert
Journal:  Front Immunol       Date:  2018-01-22       Impact factor: 7.561

Review 9.  Memory CD4+ T Cells in Immunity and Autoimmune Diseases.

Authors:  Itay Raphael; Rachel R Joern; Thomas G Forsthuber
Journal:  Cells       Date:  2020-02-25       Impact factor: 6.600

Review 10.  Revisiting the role of CD4+ T cells in cancer immunotherapy-new insights into old paradigms.

Authors:  Rong En Tay; Emma K Richardson; Han Chong Toh
Journal:  Cancer Gene Ther       Date:  2020-05-27       Impact factor: 5.987

View more
  14 in total

Review 1.  Recent Progress on Therapeutic Vaccines for Breast Cancer.

Authors:  Lianru Zhang; Xipeng Zhou; Huizi Sha; Li Xie; Baorui Liu
Journal:  Front Oncol       Date:  2022-06-06       Impact factor: 5.738

2.  Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells.

Authors:  Najla Santos Pacheco de Campos; Adriano de Oliveira Beserra; Pedro Henrique Barbosa Pereira; Alexandre Silva Chaves; Fernando Luiz Affonso Fonseca; Tiago da Silva Medina; Tiago Goss Dos Santos; Yufei Wang; Wayne Anthony Marasco; Eloah Rabello Suarez
Journal:  Int J Mol Sci       Date:  2022-05-13       Impact factor: 6.208

Review 3.  Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy.

Authors:  Zhanqi Wei; Yuewei Zhang
Journal:  Cells       Date:  2022-05-27       Impact factor: 7.666

Review 4.  Cancer-Homing CAR-T Cells and Endogenous Immune Population Dynamics.

Authors:  Emanuela Guerra; Roberta Di Pietro; Mariangela Basile; Marco Trerotola; Saverio Alberti
Journal:  Int J Mol Sci       Date:  2021-12-30       Impact factor: 5.923

5.  Functional and molecular characterization of PD1+ tumor-infiltrating lymphocytes from lung cancer patients.

Authors:  Jesse J Lipp; Limei Wang; Haitang Yang; Feng Yao; Nathalie Harrer; Stefan Müller; Sabina Berezowska; Patrick Dorn; Thomas M Marti; Ralph A Schmid; Belazs Hegedüs; Abdallah Souabni; Sebastian Carotta; Mark A Pearson; Wolfgang Sommergruber; Greg J Kocher; Sean R R Hall
Journal:  Oncoimmunology       Date:  2022-02-09       Impact factor: 8.110

Review 6.  Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies.

Authors:  Jessica Waibl Polania; Emily C Lerner; Daniel S Wilkinson; Alexandra Hoyt-Miggelbrink; Peter E Fecci
Journal:  Front Immunol       Date:  2021-11-18       Impact factor: 7.561

7.  Incidence and Risk Factors for Cerebrovascular-Specific Mortality in Patients with Colorectal Cancer: A Registry-Based Cohort Study Involving 563,298 Patients.

Authors:  Zhi-Hui Dai; Ming Tang; Yun-Liang Chen; Tao-Lan Zhang; Jing Li; Guo-Hua Lv; Yi-Guo Yan; Zhi-Hua Ouyang; Wei Huang; Ming-Xiang Zou
Journal:  Cancers (Basel)       Date:  2022-04-19       Impact factor: 6.639

Review 8.  Co-Inhibitory Molecules - Their Role in Health and Autoimmunity; Highlighted by Immune Related Adverse Events.

Authors:  Stinne R Greisen; Maithri Aspari; Bent Deleuran
Journal:  Front Immunol       Date:  2022-06-16       Impact factor: 8.786

Review 9.  Tumor accomplice: T cell exhaustion induced by chronic inflammation.

Authors:  Liguang Fang; Kunjing Liu; Cun Liu; Xiaomin Wang; Wenzhe Ma; Wenhua Xu; Jibiao Wu; Changgang Sun
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

10.  Low-Dose Radiotherapy Leads to a Systemic Anti-Inflammatory Shift in the Pre-Clinical K/BxN Serum Transfer Model and Reduces Osteoarthritic Pain in Patients.

Authors:  Thomas Weissmann; Michael Rückert; Jian-Guo Zhou; Michaela Seeling; Sebastian Lettmaier; Anna-Jasmina Donaubauer; Falk Nimmerjahn; Oliver J Ott; Markus Hecht; Florian Putz; Rainer Fietkau; Benjamin Frey; Udo S Gaipl; Lisa Deloch
Journal:  Front Immunol       Date:  2022-01-03       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.